Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Celldex Therapeutics (CLDX) Amortization - Intangibles (2016 - 2018)

Celldex Therapeutics has reported Amortization - Intangibles over the past 9 years, most recently at $224000.0 for Q1 2018.

  • Quarterly results put Amortization - Intangibles at $224000.0 for Q1 2018, changed 0.0% from a year ago — trailing twelve months through Dec 2018 was $224000.0 (down 75.0% YoY), and the annual figure for FY2018 was $224000.0, down 75.0%.
  • Amortization - Intangibles for Q1 2018 was $224000.0 at Celldex Therapeutics, roughly flat from $224000.0 in the prior quarter.
  • Over the last five years, Amortization - Intangibles for CLDX hit a ceiling of $254000.0 in Q2 2014 and a floor of $224000.0 in Q1 2017.
  • Median Amortization - Intangibles over the past 5 years was $253000.0 (2014), compared with a mean of $243882.4.
  • Biggest five-year swings in Amortization - Intangibles: changed 0.0% in 2014 and later decreased 11.81% in 2017.
  • Celldex Therapeutics' Amortization - Intangibles stood at $253000.0 in 2014, then changed by 0.0% to $253000.0 in 2015, then fell by 6.32% to $237000.0 in 2016, then fell by 5.49% to $224000.0 in 2017, then changed by 0.0% to $224000.0 in 2018.
  • The last three reported values for Amortization - Intangibles were $224000.0 (Q1 2018), $224000.0 (Q4 2017), and $224000.0 (Q3 2017) per Business Quant data.